Episodes
- Monday, October 12, 2026 · 4 min Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes
- Friday, October 9, 2026 · 6 min Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4
- Thursday, October 8, 2026 · 11 min GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow
- Wednesday, October 7, 2026 · 5 min Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors
- Tuesday, October 6, 2026 · 11 min Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front
- Monday, October 5, 2026 · 10 min Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52%
- Friday, October 2, 2026 · 10 min A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs
- Thursday, October 1, 2026 · 10 min Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts
- Wednesday, September 30, 2026 · 9 min Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD
- Tuesday, September 29, 2026 · 9 min Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin
- Monday, September 28, 2026 · 7 min Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply
- Friday, September 25, 2026 · 8 min Mounjaro Misuse in Japan, Contraband GLP-1 Pens Flood Brazil
- Thursday, September 24, 2026 · 9 min Semaglutide heart signal meets FDA import and Medicare access shifts